GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Obio Technology (shanghai) Corp Ltd (SHSE:688238) » Definitions » Net Income Including Noncontrolling Interests

Obio Technology (shanghai) (SHSE:688238) Net Income Including Noncontrolling Interests : ¥-339.4 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Obio Technology (shanghai) Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Obio Technology (shanghai)'s Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was ¥-59.5 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-339.4 Mil.


Obio Technology (shanghai) Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Obio Technology (shanghai)'s Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Obio Technology (shanghai) Net Income Including Noncontrolling Interests Chart

Obio Technology (shanghai) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.29 54.26 39.26 -127.81 -322.18

Obio Technology (shanghai) Quarterly Data
Jun19 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.30 -71.30 -76.65 -131.93 -59.51

Obio Technology (shanghai) Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-339.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Obio Technology (shanghai) Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Obio Technology (shanghai)'s Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Obio Technology (shanghai) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lane 908, Ziping Road, Building 19, International Medical Park, Pudong New Area, Shanghai, CHN, 201321
Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Executives
You Qing Rui Directors, senior managers
Pan Jun Yi Director
Yang Jia Li Core technical personnel

Obio Technology (shanghai) Headlines

No Headlines